GuideInfectious diseases

Clostridioides difficile infection: diagnosis and recurrence

Summary of IDSA/SHEA and ESCMID guidance on whom and how to test for C. difficile and how to treat recurrent episodes.

Updated 3 November 2026

When to use it

Adults with unexplained acute diarrhoea (especially inpatients or with recent antibiotics) and patients with a new episode after treated C. difficile infection.

Warning

Bezlotoxumab, recommended in the 2021 guidelines as an adjunct to prevent recurrence, was discontinued in the USA in January 2025 and its EU authorisation was withdrawn in October 2026.

Whom to test

• Patients with ≥ 3 new unformed stools in 24 hours without another explanation.

• Not in patients who received laxatives in the previous 48 hours.

• Not in asymptomatic patients (except for epidemiological studies).

• Not routinely in infants 12 months or younger, because colonisation is common.

Keep reading in the app

  • How to test
  • Definition and prevention of recurrence
  • Treatment of recurrence (IDSA/SHEA 2021, ESCMID 2021)

Practical tip

An isolated positive PCR may reflect colonisation only: interpret it with the clinical picture and, where possible, toxin detection.

2 more practical tips in the app.

Reference

Official source: IDSA/SHEA 2021 focused update guideline

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top